Federal Circuit upholds Humira invalidity finding
The US Court of Appeals for the Federal Circuit has upheld a district court’s decision to invalidate a patent covering arthritis treatment Humira, after a challenge by biopharmaceutical company AbbVie.
Hedge fund manager targets Jazz in another IPR patent challenge
A US hedge fund manager and a company he created has taken aim at Jazz Pharmaceuticals in an inter partes review patent challenge, marking the third time he has challenged a company’s patents.
MSD targets Apotex in Nasonex infringement action
Merck Sharp & Dohme has sued Apotex at the US District Court for the District of New Jersey for allegedly infringing a patent covering hay fever nasal spray Nasonex.
Novartis pays Juno $12m in cancer patent licensing deal
US anti-cancer company Juno Therapeutics and a children’s hospital have settled their patent licensing suit with pharmaceutical business Novartis and the trustees of the University of Pennsylvania.
Kramer Levin expands life sciences practice with two hires
Law firm Kramer Levin Naftalis & Frankel has hired life sciences attorneys Brian Slater and Gregory Sephton.
Schiff Hardin welcomes counsel to Chicago team
Law firm Schiff Hardin has added Cindy Ahn as counsel in its intellectual property practice group.
Forest files fifth patent lawsuit to protect Viibryd
Forest Labs, a subsidiary of Actavis, has sued InvaGen for allegedly infringing four patents covering depression drug Viibryd, in what is the fifth related lawsuit.
Federal Circuit revives Apotex blood pressure case
A US appeals court has overturned a district court's decision to deny Apotex's request for a declaratory judgment that its proposed generic blood pressure drug would not infringe a patent owned by pharmaceutical company Daiichi Sankyo.
Indian government ‘considers extending’ data exclusivity term
The Indian government is “seriously considering” extending the term of data exclusivity protection for agrochemical inventions from three to five years, it has been claimed.
Purdue moves to block oxycodone drug
Purdue Pharma has sued Collegium Pharmaceutical for allegedly infringing four of its patents relating to extended release painkiller OxyContin.
